Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Share-based Compensation (2020 - 2025)

Historic Share-based Compensation for Roivant Sciences (ROIV) over the last 6 years, with Q4 2025 value amounting to $105.0 million.

  • Roivant Sciences' Share-based Compensation fell 4891.68% to $105.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $474.5 million, marking a year-over-year decrease of 120.07%. This contributed to the annual value of $289.0 million for FY2025, which is 4478.45% up from last year.
  • Roivant Sciences' Share-based Compensation amounted to $105.0 million in Q4 2025, which was down 4891.68% from $81.8 million recorded in Q3 2025.
  • Roivant Sciences' 5-year Share-based Compensation high stood at $487.8 million for Q4 2021, and its period low was $19.3 million during Q2 2021.
  • Over the past 5 years, Roivant Sciences' median Share-based Compensation value was $81.8 million (recorded in 2025), while the average stood at $138.6 million.
  • Within the past 5 years, the most significant YoY rise in Roivant Sciences' Share-based Compensation was 27777.78% (2022), while the steepest drop was 8440.04% (2022).
  • Over the past 5 years, Roivant Sciences' Share-based Compensation (Quarter) stood at $487.8 million in 2021, then crashed by 60.54% to $192.5 million in 2022, then fell by 20.57% to $152.9 million in 2023, then surged by 34.43% to $205.5 million in 2024, then plummeted by 48.92% to $105.0 million in 2025.
  • Its Share-based Compensation was $105.0 million in Q4 2025, compared to $81.8 million in Q3 2025 and $82.2 million in Q2 2025.